CRNX241220P36000
- 0.85
- 0.000.00%
Crinetics Newsroom
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Addus Homecare (ADUS)
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $87
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $87
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Halozyme (HALO) and Crinetics Pharmaceuticals (CRNX)
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $82
Promising Outlook for Crinetics Pharmaceuticals' Paltusotine in Phase 3 Trial Drives Buy Rating
Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74
Crinetics Pharmaceuticals Analyst Ratings
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)
Morgan Stanley Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $70
H.C. Wainwright Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $81
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $82
Crinetics Pharmaceuticals: Advancing Cancer Treatment With Novel NDC Platform – A Buy Recommendation
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97